OPC-67683 - 23/08/11
Résumé |
Generic and additional names: OPC-67683
CAS name: (R)-2-Methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]-phenoxymethyl}-2,3-dihydroimidazo[2,1-b]-oxazole
CAS registry #: 681492-22-8
Molecular formula: C25H25N4F3O6
Molecular weight: 534.48
Intellectual property rights: Otsuka Pharmaceutical Co., Ltd.
Brand names: N/A
Derivatives: See structurally similar compound PA-824
Solubility: Water
Formulation and optimal human dosage: A patent for OPC-67683 was filed by Otsuka in 2003. A phase I OPC-67683 clinical trial was performed in Japan in early 2006, but results are currently unavailable. Otsuka filed a patent through the Patent Cooperative Treaty (PCT) process to cover 2,3-dihydro-6-nitroimidazo-(2,1-b)oxazole compounds for TB treatment.
Vol 88 - N° 2
P. 132-133 - mars 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?